Peptide Initiative

Peptides · Peptide comparison

Adrenomedullin vs BPC-157

A powerful vasodilatory peptide that relaxes blood vessels and helps your body maintain healthy fluid balance and blood pressure.

The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeAdrenomedullin10–10 ng/kg/minBPC-157250–500 mcg
FrequencyAdrenomedullinOnce dailyBPC-157Once daily
AdministrationAdrenomedullinIntravenous infusionBPC-157Subcutaneous injection
Cycle lengthAdrenomedullinOngoing/indefiniteBPC-1574-6 weeks
Onset speedAdrenomedullinModerate (1-2 weeks)BPC-157Moderate (1-2 weeks)
Evidence levelAdrenomedullinModerate human trials (Phase 1-2)BPC-157Strong preclinical (extensive animal studies)

Efficacy

Benefit ratings

Cardiovascular Support

Adrenomedullin82%
BPC-157No recorded rating

Tissue Protection

Adrenomedullin78%
BPC-157No recorded rating

Immune Function

Adrenomedullin74%
BPC-157No recorded rating

Primary Benefit

AdrenomedullinNo recorded rating
BPC-15785%

Secondary Benefit

AdrenomedullinNo recorded rating
BPC-15778%

Additional Benefit

AdrenomedullinNo recorded rating
BPC-15772%

Technical data

Compound specifications

Adrenomedullin

Molecular formula
C264H406N80O77S3
Molecular weight
6029 Da (Daltons)
Half-life
Approximately 20-30 minutes in plasma (rapid metabolism)
Bioavailability
Parenteral administration only; peptide undergoes proteolytic cleavage in circulation
CAS number
148498-78-6

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0

Protocols

Dosing compared

Adrenomedullin

Intravenous

  • 5 ng/kg/minContinuous infusion, 8 hours per day · 14 days (trial protocol)Adrenomedullin is given as a slow drip into a vein in clinical trials, not by self-injection. This low dose was the bottom step tested for steroid-resistant ulcerative colitis. [4]
  • 10 ng/kg/minContinuous infusion, 8 hours per day · 14 days (trial protocol)Middle dose tested in the ulcerative colitis trial. [4]
  • 15 ng/kg/minContinuous infusion, 8 hours per day · 14 days (trial protocol)This higher dose was the only one that significantly improved disease scores in the trial. The same 15 ng/kg/min rate was also tested safely in healthy volunteers. [4][5]

BPC-157

Subcutaneous

  • 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
  • 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
  • 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].

Applications

Best suited for

Adrenomedullin

Cardiovascular health optimization
Adrenomedullin is particularly well-suited for individuals focused on cardiovascular health optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Maintaining healthy blood pressure
Adrenomedullin is particularly well-suited for individuals focused on maintaining healthy blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from illness or sepsis
Adrenomedullin is particularly well-suited for individuals focused on recovery from illness or sepsis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tissue protection and oxygen delivery
Adrenomedullin is particularly well-suited for individuals focused on tissue protection and oxygen delivery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

BPC-157

Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]

Safety profile

Side effects

Adrenomedullin

Common

  • Mild discomfort at treatment site
  • Excessive blood pressure lowering (hypotension)
  • Headaches (from pressure changes)
  • Flushing and mild facial redness
  • Dizziness or lightheadedness
  • Mild electrolyte shifts
  • Localized injection site reactions
  • Increased urination (natriuretic effect)

Serious

  • Severe allergic reaction

BPC-157

Common

  • Injection site redness
  • Mild nausea
  • Dizziness

Uncommon

  • Headache
  • Fatigue
  • Hot/cold sensations

Serious

  • Allergic reaction

Research status

Safety & evidence

Adrenomedullin

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Adrenomedullin safety in humans is poorly characterized, with clinical data limited to observational studies and small uncontrolled trials in cardiovascular patients. Animal studies demonstrate potent vasodilatory effects that could lower blood pressure dangerously, particularly in patients on antihypertensive medications. No human pharmacokinetic studies have established safe doses, and potential for hypotension, electrolyte disturbances, and off-target vasodilation effects exists. The peptide crosses the blood-brain barrier and affects central nervous system function in animal models, raising concerns about neurological effects at higher doses.

Contraindications

  • Severe hypotension or shock states
  • Concurrent use with certain vasopressor medications
  • Pregnancy and breastfeeding
  • Severe kidney or liver dysfunction

BPC-157

Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

  • Pregnancy
  • Breastfeeding
  • Active cancer
  • History of cancer

Decision guide

Which is right for you?

Adrenomedullin

Choose Adrenomedullin if…

  • Cardiovascular health optimization
  • Maintaining healthy blood pressure
  • Recovery from illness or sepsis
  • Tissue protection and oxygen delivery

BPC-157

Choose BPC-157 if…

  • Injury recovery
  • Post-surgery healing
  • Chronic pain management
  • Gut health